Faes enters deals with Pfizer and Cinfa
Faes has retained the right to directly commercialise the product in Mexico under co-marketing conditions. Faes has also signed licensing deals for bilastine in Europe, India, South Korea, the Middle East and North Africa.
Separately, Faes has signed an agreement with Laboratorios Cinfa for the commercialisation and distribution of generic products in Portugal.
The agreement will take effect from the beginning of next year an will hope to leverage Faesás knowledge of the Portuguese pharmaceutical market with Cinfaás generics experience in the country as well as in Spain, the companies said. The companies estimate that the Portuguese generics market is worth more than €500 million annually.
(*) Nota: Scrip es la revista líder de la industria farmacéutica y una de las más prestigiosas. Es editada en Gran Bretaña desde 1972.
